Interestingly, in contrast to the above, high expression levels of RIPK1 and RIPK3 in human pancreatic cancer cells predicted enhanced migration and invasion of tumor cells,41 whereas low expression of MLKL was linked to reduced overall survival (OS) in patients with early resectable pancreatic cancer and reduced recurrence-free survival and OS in pancreatic cancer patients receiving adjuvant chemotherapy,264 which suggests necroptosis effectors differentially influence tumor pathogenesis in different contexts, and this heterogeneity has not been explained so far. The gene discussed is RIPK3; the disease is pancreatic neoplasm.